| Aggressive B-Cell Non-Hodgkin Lymphoma studied in …STUDIED_INderived200 of 400show all (up to 200) |
|---|
| → studied in | NCT06649812Phase 2 · recruiting Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03223610Phase 1/Phase 2 · recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02992522Phase 1 · active not recruiting Obinutuzumab, Venetoclax, and Lenalidomide in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03015896Phase 1/Phase 2 · completed Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06453044Phase 2 · recruiting Mosunetuzumab and Polatuzumab Vedotin for the Treatment of Patients With Relapsed or Refractory Grade 1-3a Follicular Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05359211Phase 1 · completed NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05025800Phase 1/Phase 2 · active not recruiting ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05627245Phase 1 · active not recruiting Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06395103Phase 1/Phase 2 · recruiting Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07731789Phase 2 · not yet recruiting Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07819396Phase 2 · not yet recruiting Depletion of CD45RA Positive Naive T Cells for the Prevention of Graft Versus Host Disease in Older Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia or Myelodysplastic Syndrome · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01318317Phase 1/Phase 2 · active not recruiting Genetically Engineered Lymphocyte Therapy After Peripheral Blood Stem Cell Transplant in Treating Patients With High-Risk, Intermediate-Grade, B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01849263Phase 2 · active not recruiting Ibrutinib in Treating Patients With Relapsed or Refractory Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04665765Phase 2 · active not recruiting Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06830031Phase 1 · recruiting Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07098364Phase 1/Phase 2 · suspended ST-067 in Combination With CD19-Directed CAR T-Cell Therapy (Liso-cel) in Relapsed/Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07814001Phase 2 · not yet recruiting Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell Therapy · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03625037Phase 1/Phase 2 · active not recruiting First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01961063Phase 1 · active not recruiting Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | AIDS-Related Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07432022Phase 1/Phase 2 · recruiting A Phase I/II Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of the EMB-07 Combination Therapy in Patients With Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06784726Phase 2 · recruiting Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04464200Phase 1 · active not recruiting 19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Cancers · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06442475Phase 2 · recruiting Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03959085Phase 3 · recruiting Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05389423Phase 1 · recruiting Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06536049Phase 1/Phase 2 · recruiting Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03150329Phase 1 · active not recruiting Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL. · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05294731Phase 1/Phase 2 · recruiting Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404088Phase 2 · active not recruiting Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06710418NA · recruiting Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07724457Phase 2/Phase 3 · not yet recruiting Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03198026Phase 2 · active not recruiting Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients With Indolent Non-Hodgkin's Lymphomas · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06927466Phase 1 · recruiting A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia. · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07735533Phase 1/Phase 2 · not yet recruiting A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07662928Phase 2 · not yet recruiting Epcoritamab in Combination With Dose Adjusted EPOCH-R for High-risk Burkitt Lymphoma (BL), The BEDROCK Study · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Adult Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07649304Phase 1 · not yet recruiting AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study") · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | AIDS-Related Diffuse Large B-cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06340737Phase 1 · recruiting AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07758673Phase 1 · not yet recruiting Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03136146Phase 2 · recruiting Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03504644Phase 1/Phase 2 · active not recruiting Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03656835NA · active not recruiting Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05990465Phase 1 · recruiting LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06533579Phase 1/Phase 2 · recruiting Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19) · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07750886recruiting Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL) · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02443077Phase 3 · active not recruiting Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07069699Phase 1/Phase 2 · recruiting Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02981628Phase 2 · active not recruiting Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03914625Phase 3 · active not recruiting A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01479842Phase 1 · active not recruiting Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05821088Phase 2 · active not recruiting Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06471738Phase 2 · recruiting Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07714421Phase 1 · not yet recruiting Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit Patients · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01371630Phase 1/Phase 2 · recruiting Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Large B-Cell Lymphoma with 11q Aberration | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05077527Phase 1 · recruiting Immune Cell Therapy (CAR-T) for the Treatment of Patients With HIV and B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | AIDS-Related Diffuse Large B-cell Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05303792Phase 2 · active not recruiting Comparing Inotuzumab Combined With Low Intensity Chemotherapy Plus Blinatumomab to Usual Chemotherapy Plus Blinatumomab in Older Adults With CD22+ B-cell Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05672251Phase 2 · recruiting Loncastuximab Tesirine and Mosunetuzumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03269669Phase 2 · active not recruiting Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03810196NA · recruiting CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04799275Phase 2/Phase 3 · active not recruiting Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05805605Phase 2 · recruiting Allo HSCT Using RIC and PTCy for Hematological Diseases · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05653271Phase 1 · completed ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02520791Phase 1 · active not recruiting Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04205409Phase 2 · completed Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01815749Phase 1 · active not recruiting Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Adult Grade III Lymphomatoid Granulomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03314974Phase 2 · recruiting Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04257578Phase 1/Phase 2 · active not recruiting Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02332980Phase 2 · completed Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04545762Phase 1 · recruiting Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05455697Phase 1/Phase 2 · active not recruiting Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07637929not yet recruiting Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06131801recruiting Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06948786Phase 2 · recruiting Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04739813Phase 1 · active not recruiting Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05412290Phase 1 · active not recruiting Mosunetuzumab Consolidation Therapy After autoSCT in r/r Aggressive B Cell Lymphoma · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04195633Phase 2 · recruiting Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01190930Phase 3 · completed Risk-Adapted Chemotherapy in Treating Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia or Localized B-Lineage Lymphoblastic Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Adult B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05480449Phase 1/Phase 2 · recruiting Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy) · condition mapped PROBABILISTIC · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01962636NA · terminated Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02877303Phase 2 · recruiting Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients With B Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02797470Phase 1/Phase 2 · active not recruiting Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02362035Phase 1/Phase 2 · completed ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05169658Phase 2 · completed Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05794880NA · recruiting MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03038672Phase 2 · active not recruiting Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06014762Phase 1 · active not recruiting P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07097363Phase 2 · recruiting Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05507541Phase 2 · active not recruiting TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07545603Phase 2 · recruiting Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06859008Phase 1 · recruiting Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01384513Phase 2 · completed A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Adult Grade III Lymphomatoid Granulomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04491370Phase 1/Phase 2 · recruiting Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07476105NA · not yet recruiting Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line Treatment · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06544265Phase 1 · recruiting SynKIR-310 for Relapsed/Refractory B-NHL · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04450173Phase 2 · active not recruiting Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04404660Phase 1/Phase 2 · active not recruiting A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL) · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04488354Phase 1 · completed Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04088890Phase 1 · completed Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05674175Phase 1/Phase 2 · recruiting Co-administration of CART22-65s and huCART19 for B-ALL · condition mapped PROBABILISTIC · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06026319Phase 1 · recruiting CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02213913Phase 1/Phase 2 · completed Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Adult Grade III Lymphomatoid Granulomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02446457Phase 2 · active not recruiting Rituximab and Pembrolizumab With or Without Lenalidomide in Treating Patients With Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04425421recruiting Recommendations for the Treatment of Children With Burkitt's Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05755087Phase 1 · recruiting Tegavivint for Treating Patients With Relapsed or Refractory Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04512716early Phase 1 · recruiting Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05544019Phase 1 · recruiting Study of SGR-1505 in Mature B-Cell Neoplasms · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04690595Phase 1 · active not recruiting BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04883437Phase 2 · recruiting Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05633615Phase 2 · recruiting Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04285268Phase 2 · withdrawn Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05583149Phase 2 · active not recruiting Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01199562active not recruiting Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Adult Grade III Lymphomatoid Granulomatosis | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06834373Phase 2 · recruiting Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06575686Phase 2 · suspended Epcoritamab and Tazemetostat for the Treatment of Relapsed or Refractory Grade I-IIIa Follicular Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05464329Phase 1 · active not recruiting Mosunetuzumab in Combination With Platinum-Based Salvage Chemotherapy in Patients With Relapsed/Refractory Aggressive B Cell Lymphoma · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03674411Phase 2 · active not recruiting Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04191187Phase 2 · completed Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02568553Phase 1 · completed Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01286272Phase 2 · completed Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02337985Phase 1 · active not recruiting Gene Therapy and Combination Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | AIDS-Related Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02996773Phase 1 · completed Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03375619recruiting Long-term Follow-up Study of Patients Receiving CAR-T Cells · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00776373Phase 1/Phase 2 · terminated Rapamycin in With High-Dose Etoposide and Cytarabine in Relapsed/Refractory Aggressive Lymphoid Malignancies · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05890352Phase 2 · recruiting Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05565417Phase 1/Phase 2 · active not recruiting Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05270057Phase 1 · active not recruiting Loncastuximab Tesirine in Combination With DA-EPOCH-R in Patients With Previously Untreated Aggressive B-cell Lymphoid Malignancies · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02153580Phase 1 · active not recruiting Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Adult Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07168291early Phase 1 · not yet recruiting Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06278181completed Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Endemic Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02393157Phase 2 · recruiting Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06220097Phase 2 · active not recruiting Mitoxantrone Hydrochloride Liposome Injection-containing Bridging Regimen and CD19-targeting CAR-T Therapies · condition mapped PROBABILISTIC · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02722668Phase 2 · completed UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01995669Phase 1/Phase 2 · completed Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00001337Phase 2 · completed Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03742258Phase 1 · completed Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06940960NA · recruiting JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia · condition mapped PROBABILISTIC · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02871219Phase 2 · completed Obinutuzumab and Lenalidomide in Treating Patients With Previously Untreated Stage II-IV Grade 1-3a Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04034446early Phase 1 · terminated CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL) · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06890065NA · recruiting JY231(JY231) Injection for the Treatment of Relapsed/Refractory B Cell Lymphoma/ Leukemia · condition mapped PROBABILISTIC · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03583424Phase 1/Phase 2 · completed Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05326243Phase 1/Phase 2 · recruiting Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05377307recruiting Long-term Follow-up Study of Lentiviral-based Gene-edited Immune Cell Therapy · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02823327terminated Clinical and Genomic Factors for Prognosis of AIDS Primary Effusion Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | AIDS-Related Primary Effusion Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06961500Phase 2 · not yet recruiting Obinutuzumab With CHOP Versus Obinutuzumab With Bendamustine in the Treatment of Newly Diagnosed Follicular Lymphoma Grade 3A · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01184885early Phase 1 · completed A Pilot Study to Determine the Safety and Tolerability of Sirolimus Given With Hyper-CVAD Chemotherapy · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00719888Phase 2 · completed Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06060782Phase 1 · recruiting Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06093841Phase 2 · active not recruiting Relmacabtagene Autoleucel As Second-Line Therapy in Adult Patients with Aggressive B-cell NHL · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06796517recruiting Immunotherapy in Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05263583Phase 2 · active not recruiting Sepantronium Bromide for the Treatment of High-grade B-cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02112526Phase 1 · completed Acalabrutinib (ACP-196), a Btk Inhibitor, for Treatment of de Novo Activated B-cell (ABC) Subtype of Diffuse Large B-Cell Lymphoma · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03410901Phase 1 · completed TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02927964Phase 1/Phase 2 · completed TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05202782Phase 2 · active not recruiting Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06635330Phase 1/Phase 2 · recruiting Safety and Efficacy of CAR T Cell Therapy in Patients with R/r B-ALL · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02532257Phase 2 · completed Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04659044Phase 2 · terminated Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05333302Phase 1 · unknown Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma · condition mapped PROBABILISTIC · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01793233completed Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04450069Phase 1 · completed CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06287398Phase 2 · recruiting Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients With Relapsed LBCL · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04933617Phase 1 · terminated Copanlisib With Dose-Adjusted EPOCH-R in Relapsed and Refractory Burkitt Lymphoma and Other High-Grade B-cell Lymphomas · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05422066Phase 2 · unknown Selinexor Plus R-CHOP in High-risk GCB-subtype Diffuse Large B-Cell Lymphoma · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02199184Phase 2 · completed Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | AIDS-Related Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04995536Phase 1 · withdrawn CpG-STAT3 siRNA CAS3/SS3 and Localized Radiation Therapy for the Treatment of Relapsed/Refractory B-Cell NHL · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06355739NA · recruiting CD19-targeted CAR T Cell Autotransfusion for the Treatment of Recurrent/Refractory B-cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma in Children With CD19+ · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01588015Phase 1 · completed Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Adult Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02636322Phase 2 · completed Smart Start: A Phase II Study of Rituximab, Lenalidomide, and Ibrutinib · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Unclassifiable | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04858568completed Immune Responses to COVID-19 Vaccination in Lymphoma Patients · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01769222Phase 1 · terminated Ipilimumab and Local Radiation for Selected Solid Tumors · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Adult Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03833180Phase 1 · completed A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001) · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04220008Phase 2 · withdrawn Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03864419Phase 1 · terminated Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01523223Phase 1 · completed Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Adult Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01193842Phase 1/Phase 2 · completed Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma or Other Aggressive B-Cell Lymphomas · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | AIDS-Related Plasmablastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04870853unknown Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01000753completed Collecting and Storing Tissue Samples From Patients With Rare or Cutaneous Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02661035Phase 2 · completed Allo HSCT Using RIC for Hematological Diseases · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01044745Phase 2 · terminated Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Adult Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03010358Phase 1/Phase 2 · completed Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3a Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02134782NA · terminated Yoga Fatigue Study · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05020392Phase 3 · unknown Autologous Cells Derived Anti-CD19 CAR-Engineered T Cells With Concurrent BTK Inhibitor for B Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02847130completed Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Childhood Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05144347Phase 1 · terminated Study of XL114 in Subjects With Non-Hodgkin's Lymphoma · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Diffuse Large B-Cell Lymphoma Activated B-Cell Type | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03991884Phase 1 · completed Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | B Lymphoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04156828Phase 1 · terminated Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01029366Phase 1 · completed CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02588456Phase 1 · terminated Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05733650approved for marketing Expanded Access Program for Epcoritamab · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Grade 3b Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03677128NA · completed Mobile Health Case Management System for Reducing Pediatric Treatment Abandonment · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05840289unknown A Study on Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive B-Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Aggressive B-Cell Non-Hodgkin Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01925131Phase 1 · completed S1312, Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Leukemia · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Adult Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01092182Phase 2 · completed Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01028716Phase 2 · terminated Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05693519unknown GastroIntestinal Cancer in Children and Adolescents · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00096460Phase 2/Phase 3 · terminated Autologous or Donor Stem Cell Transplantation in Treating Patients With Recurrent Non-Hodgkin's Lymphoma (BMT CTN 0202) · condition mapped CURATED_BROADER · 400 trials mapped (123 active) | — | — | Grade 3 Follicular Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00849147Phase 2 · completed Bone Marrow Transplant From Partially Matched Donors and Nonmyeloablative Conditioning for Blood Cancers (BMT CTN 0603) · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00864227Phase 2 · completed Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604) · condition mapped ONTOLOGY_EXACT · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01859819Phase 2 · completed Treatment for Advanced B-Cell Lymphoma · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01775475Phase 2 · completed Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma · condition mapped ALIAS · 400 trials mapped (123 active) | — | — | AIDS-Related Immunoblastic Lymphoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02618109Phase 4 · terminated Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia · condition mapped PROBABILISTIC · 400 trials mapped (123 active) | — | — | Burkitt Lymphoma | 1 | Observed | clinicaltrials | graph → |